Evolus Inc (EOLS) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amid Market Challenges [Yahoo! Finance]
Evolus, Inc. (EOLS)
Last evolus, inc. earnings: 2/25 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
us.evolis.com/investor-relations
Company Research
Source: Yahoo! Finance
This article first appeared on GuruFocus Fourth Quarter Global Net Revenue: $90.3 million, representing 14% growth over 2024. Full Year Global Net Revenue: $297.2 million, up 12% compared to 2024. Jeuveau Revenue: $83.1 million in the fourth quarter. Evolysse Revenue: $7.2 million in the fourth quarter. International Revenue: 8% of 2025 global revenues, up from 5% in 2024. Fourth Quarter Gross Margin: Approximately 66% reported, 67% adjusted. Full Year Gross Margin: Approximately 66% reported, 67% adjusted. Fourth Quarter GAAP Operating Expenses: $55.1 million. Fourth Quarter Non-GAAP Operating Expenses: $53.0 million. Full Year GAAP Operating Expenses: $229.8 million. Full Year Non-GAAP Operating Expenses: $209.7 million. Fourth Quarter Non-GAAP Operating Income: $7.1 million. Cash Balance at End of Fourth Quarter: $53.8 million. 2026 Revenue Guidance: $327 million to $337 million, representing 10% to 13% growth over 2025. 2026 Adjusted Gross Profit Mar
Show less
Read more
Impact Snapshot
Event Time:
EOLS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EOLS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EOLS alerts
High impacting Evolus, Inc. news events
Weekly update
A roundup of the hottest topics
EOLS
News
- AEON Biopharma Abstract Accepted for Presentation at 2026 American Academy of Neurology (AAN) Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Evolus, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]Yahoo! Finance
- Evolus (EOLS) had its "buy" rating reaffirmed by BTIG Research. They now have a $13.00 price target on the stock.MarketBeat
- Evolus, Inc. (EOLS) Q4 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Evolus outlines 2026 revenue guidance of $327M–$337M while expanding international presence and product portfolio [Seeking Alpha]Seeking Alpha
EOLS
Earnings
- 3/3/26 - Beat
EOLS
Sec Filings
- 3/3/26 - Form S-8
- 3/3/26 - Form 10-K
- 3/3/26 - Form 8-K
- EOLS's page on the SEC website